su011248

Mast Cell Leukemia

National Cancer Institute (NCI)Phase 2Dormant

B

59/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 44/ 100
Competitive Position: 95/ 100

Competitive context

10 Active assets in the Mast Cell Leukemia cohort.

Asset / Sponsor	Phase	Rating
CYCLOSPORIN A Stanford University	Phase 2	BB
Monomethyl Fumarate Stanford University	Phase 2	BB
Fludarabine Fred Hutchinson Cancer Center	Phase 2	BB
Avapritinib Blueprint Medicines Corporation	Phase 2	BB
Tas-102 National Cancer Institute (NCI)	Phase 2	B

View all 21 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant

BBB

Indicative ·

75 / 100

Pancreatic Neuroendocrine TumorDormant

BB

Indicative ·

69 / 100

Renal Cell CarcinomaDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.